Peer-influenced content. Sources you trust. No registration required. This is HCN.
Blood Advances
The study confirmed the high unmet need among older adults with AML, namely that overall survival (OS) without transplant is poor and consistent with other studies. The authors also remark that a “definitive evidence-based recommendation favoring venetoclax and azacitidine (ven/aza) or CPX-351 in older adults will require a randomized trial.”
Hematology/Oncology July 18th 2022
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS